CRBU Key Statistics, Chart & Performance
The current stock price of CRBU is 1.41 USD. In the past month the price decreased by -11.32%. In the past year, price decreased by -1.4%.
CRBU Technical Analysis
CRBU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRBU. The financial health of CRBU is average, but there are quite some concerns on its profitability.
CRBU Financial Highlights
Over the last trailing twelve months CRBU reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS decreased by -3.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.58% | ||
| ROE | -110.77% | ||
| Debt/Equity | 0 |
CRBU Forecast & Estimates
14 analysts have analysed CRBU and the average price target is 11.09 USD. This implies a price increase of 686.7% is expected in the next year compared to the current price of 1.41.
For the next year, analysts expect an EPS growth of 0.58% and a revenue growth -4.31% for CRBU
CRBU Ownership
About CRBU
Company Profile
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 147 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Company Info
CARIBOU BIOSCIENCES INC
2929 7Th Street, Ste 120
Berkeley CALIFORNIA US
Employees: 147
Phone: 15109826030
CARIBOU BIOSCIENCES INC / CRBU FAQ
Can you describe the business of CARIBOU BIOSCIENCES INC?
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 147 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
What is the current price of CRBU stock?
The current stock price of CRBU is 1.41 USD. The price decreased by -4.73% in the last trading session.
What is the dividend status of CARIBOU BIOSCIENCES INC?
CRBU does not pay a dividend.
How is the ChartMill rating for CARIBOU BIOSCIENCES INC?
CRBU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is CRBU stock listed?
CRBU stock is listed on the Nasdaq exchange.
Who owns CARIBOU BIOSCIENCES INC?
You can find the ownership structure of CARIBOU BIOSCIENCES INC (CRBU) on the Ownership tab.
What is the Short Interest ratio of CARIBOU BIOSCIENCES INC (CRBU) stock?
The outstanding short interest for CARIBOU BIOSCIENCES INC (CRBU) is 7.78% of its float.